全文获取类型
收费全文 | 9761篇 |
免费 | 570篇 |
国内免费 | 145篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 44篇 |
妇产科学 | 5篇 |
基础医学 | 988篇 |
口腔科学 | 14篇 |
临床医学 | 1165篇 |
内科学 | 126篇 |
皮肤病学 | 2篇 |
神经病学 | 5495篇 |
特种医学 | 61篇 |
外科学 | 93篇 |
综合类 | 891篇 |
现状与发展 | 1篇 |
预防医学 | 267篇 |
眼科学 | 7篇 |
药学 | 1193篇 |
9篇 | |
中国医学 | 104篇 |
肿瘤学 | 8篇 |
出版年
2024年 | 21篇 |
2023年 | 92篇 |
2022年 | 148篇 |
2021年 | 262篇 |
2020年 | 274篇 |
2019年 | 252篇 |
2018年 | 212篇 |
2017年 | 256篇 |
2016年 | 344篇 |
2015年 | 325篇 |
2014年 | 557篇 |
2013年 | 738篇 |
2012年 | 539篇 |
2011年 | 622篇 |
2010年 | 525篇 |
2009年 | 487篇 |
2008年 | 567篇 |
2007年 | 560篇 |
2006年 | 534篇 |
2005年 | 407篇 |
2004年 | 325篇 |
2003年 | 297篇 |
2002年 | 257篇 |
2001年 | 188篇 |
2000年 | 136篇 |
1999年 | 134篇 |
1998年 | 149篇 |
1997年 | 146篇 |
1996年 | 130篇 |
1995年 | 96篇 |
1994年 | 91篇 |
1993年 | 77篇 |
1992年 | 84篇 |
1991年 | 62篇 |
1990年 | 72篇 |
1989年 | 50篇 |
1988年 | 45篇 |
1987年 | 57篇 |
1986年 | 49篇 |
1985年 | 51篇 |
1984年 | 47篇 |
1983年 | 26篇 |
1982年 | 35篇 |
1981年 | 39篇 |
1980年 | 29篇 |
1979年 | 22篇 |
1978年 | 13篇 |
1977年 | 19篇 |
1976年 | 13篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的观察奥兰扎平治疗精神分裂症的临床疗效与安全性.方法选择58例精神分裂症病人,开始给予奥兰扎平5mg*d-1,3d后根据临床疗效、副反应情况酌情增加剂量,最大剂量不超过20mg*d-1,治疗8周.治疗前及治疗后每2周用PANSS、CGI、TESS量表评定1次.结果治疗后PANSS总分、各因子分较治疗前显著下降(P<0.01),副反应主要有抗胆碱症状、过度镇静、体重增加、一过性丙氨酸氨基转移酶升高.结论奥兰扎平是一种安全、有效、副作用较轻的抗精神病药. 相似文献
2.
3.
Acetylcholinesterase inhibitors may improve myelin integrity. 总被引:2,自引:0,他引:2
George Bartzokis 《Neuropsychopharmacology》2007,62(4):294-301
Recent clinical trials have revealed that cholinergic treatments are efficacious in a wide spectrum of neuropsychiatric disorders that span the entire human lifespan and include disorders without cholinergic deficits. Furthermore, some clinical and epidemiological data suggest that cholinergic treatments have disease modifying/preventive effects. It is proposed that these observations can be usefully understood in a myelin-centered model of the human brain. The model proposes that the human brain's extensive myelination is the central evolutionary change that defines our uniqueness as a species and our unique vulnerability to highly prevalent neuropsychiatric disorders. Within the framework of this model the clinical, biochemical, and epidemiologic data can be reinterpreted to suggest that nonsynaptic effects of cholinergic treatments on the process of myelination and myelin repair contributes to their mechanism of action and especially to their disease modifying/preventive effects. The ability to test the model in human populations with safe and noninvasive imaging technologies makes it possible to undertake novel clinical trial efforts directed at primary prevention of some of the most prevalent and devastating of human disorders. 相似文献
4.
Twenty-four chronic schizophrenic long-stay hospital patients were identified, who had not received neuroleptic drugs for 8–30 (average 8 months) and met or exceeded a minimum criterion of severity of negative symptoms. They were rendomly alocated to either sulpiride 200 mg twice daily or matching placebo, on a double-blind basis for 12 weeks. The results showed that low-dose sulpiride was significantly better than placebo in relation to improvements in negative symptoms. The changes in social behaviour were complex and not obviously related to symptom improvement; exhibited abnormal behaviour, a major factor in preventing successful return to the community, consistently improved only on the active drug. 相似文献
5.
Guochuan Tsai Hsien-Yuan Lane Pinchen Yang Mian-Yoon Chong Nicholas Lange 《Neuropsychopharmacology》2004,55(5):452-456
BACKGROUND: Hypofunction of N-methyl-D-aspartate glutamate receptor had been implicated in the pathophysiology of schizophrenia. Treatment with D-serine or glycine, endogenous full agonists of the glycine site of N-methyl-D-aspartate receptor, or D-cycloserine, a partial agonist, improve the symptoms of schizophrenia. N-methylglycine (sarcosine) is an endogenous antagonist of glycine transporter-1, which potentiates glycine's action on N-methyl-D-aspartate glycine site and can have beneficial effects on schizophrenia. METHODS: Thirty-eight schizophrenic patients were enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/d), which was added to their stable antipsychotic regimens. Twenty of them received risperidone. Measures of clinical efficacy and side effects were determined every other week. RESULTS: Patient who received sarcosine treatment revealed significant improvements in their positive, negative, cognitive, and general psychiatric symptoms. Similar therapeutic effects were observed when only risperidone-treated patients were analyzed. Sarcosine was well-tolerated, and no significant side effect was noted. CONCLUSIONS: Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone. The significant improvement with the sarcosine further supports the hypothesis of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Glycine transporter-1 is a novel target for the pharmacotherapy to enhance N-methyl-D-aspartate function. 相似文献
6.
邹新花 《现代中西医结合杂志》2005,14(10):1274-1276
目的 探讨抗精神病药(APD)引起患者体质量增加及其相关因素。方法 对6 7例首次住院单用APD治疗的精神分裂症患者进行住院及出院后4个月的随访评估。结果 各时点体质量增加与GI评分无相关性,在出院时与BPRS、SAPS减分值有相关性,而随访期与SANS减分值有相关意义。逐步回归分析显示,在α=0 .0 5水平上,进入回归方程的因素依次为:APD品种,最大服药剂量与服药时间的积,阴性症状,病前1a最佳功能水平。结论 APD治疗中的体质量增加是与疗效无关的药物不良反应,受药物、精神症状及综合社会心理因素等方面的影响,而饮食与活动的中介作用不应低估。控制体质量增加有重要的医学及社会意义。 相似文献
7.
国产奎硫平合并舒必利治疗难治性精神分裂症 总被引:1,自引:0,他引:1
目的:了解舒必利合并国产奎硫平(启维)治疗难治性精神分裂症的疗效和安全性。方法:26例符合CCMD-Ⅲ精神分裂症诊断标准且临床判断属于难治性病人,予舒必利合并奎硫平治疗,疗程8周,分别在治疗前及治疗后进行阳性与阴性症状量表(PANSS)和不良反应状量表(TESS)评定。结果:合并治疗8周后总有效率65.3%。PANSS阳性、阴性及一般精神病理评分于治疗前后均有显著差异(P<0.01)。TESS总分治疗前后无显著差异(P>0.05)。副反应主要为肌张力增高、失眠、体重增加、静坐不能。结论:对于舒必利治疗反应不佳的难治性精神分裂症病人合并奎硫平治疗仍可取得较好的临床效果,安全性较高,耐受性及依从性好,可作为临床治疗难治性病人的方法之一。 相似文献
8.
Donald E. Addington Emily McKenzie Jean Addington Scott Patten Harvey Smith Carol Adair 《Early intervention in psychiatry》2007,1(2):157-167
Aim: The purpose of this project was to operationalize and apply a previously identified set of performance measures designed to evaluate services for those experiencing a first episode of a schizophrenia spectrum disorder. Methods: Operational definitions were developed for previously identified measures through an iterative process of discussions between clinical experts and health‐care evaluators. Data were collected from existing sources including corporate databases, clinical databases and chart review. Results: Definitions were developed for 44 measures covering seven of eight domains recommended for service level evaluation by the Canadian Institute for Health Information domains. Forty measures could be calculated. Conclusions: The measures represent a comprehensive set of performance measures suitable for the evaluation of services for people with a first‐episode psychosis. The measures could be used by other services in order to establish standards and norms for routine clinical practice. 相似文献
9.
10.
H. Kitamura T. Shioiri M. Itoh Y. Sato K. Shichiri & T. Someya 《Journal of intellectual disability research : JIDR》2007,51(10):812-820
Background Evidence suggests that, as a group, patients with schizophrenia have intellectual deficits that may precede the manifestation of psychotic symptoms; however, how successfully intelligence tests are able to discriminate schizophrenia from other psychotic disorders has yet to be investigated in detail. Methods Using Wechsler Adult Intelligence Scale – Revised (WAIS‐R) data for 55 inpatients with schizophrenia and 28 inpatients with non‐schizophrenic psychotic disorders (NSPD) (schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder due to a general medical condition, and psychotic disorders not otherwise specified), intelligence performance was compared between schizophrenia and NSPD and among different subtypes of schizophrenia. Results There were no significant differences in intelligence quotient (IQ), verbal IQ (VIQ) and performance IQ (PIQ) discrepancy, and subtest scores of WAIS‐R between the patients with schizophrenia and those with NSPD. These diagnostic groups were not discriminated well by any WAIS‐R variables. Schizophrenia patients with prominent negative symptoms, on the other hand, had a significantly larger IQ discrepancy (VIQ > PIQ) than those without prominent negative symptoms and NSPD patients. Intelligence performance in schizophrenia did not differ with respect to diagnostic subtypes and longitudinal courses. Conclusions The current study failed to show diagnostic usefulness of WAIS‐R in discriminating schizophrenia and other psychoses. A diagnosis of schizophrenia does not significantly impact intellectual deficits in psychotic disorders. 相似文献